Sarcoidosis with Both Plaques and Subcutaneous Nodules Associated with Combination Therapy with Peginterferon α-2a and Ribavirin
نویسندگان
چکیده
A 64-year-old woman with hepatitis C was treated using combination therapy with peginterferon α-2a and ribavirin. After 3 months, she presented with raised nodules on her knees and elbows. After 8 months, she developed painful subcutaneous nodules on her forearms. We diagnosed sarcoidosis with both plaques and subcutaneous nodules associated with combination therapy with peginterferon α-2a and ribavirin. Sarcoidosis with both plaques and subcutaneous nodules is very rare. The patient had a sustained Th2 response in the liver. And a sustained Th1 response occurred only in the skin. It is likely that, for this reason, sarcoidosis was localized to the skin, and the patient developed sarcoidosis with both plaques and subcutaneous nodules.
منابع مشابه
مقایسه پاسخ درمانی مداوم بیماران مبتلا به هپاتیت مزمن C با رژیم اینترفرون معمولی در مقابل پگیلیتد اینترفرون
Introduction: Based on data from recent trials, peginterferon and ribavirin combination therapy is the standard of care in treating patients with chronic HCV infection, but because of high costs, many patients may deprive from treatment. Methods: We conducted a clinical trial on HCV patients in Yazd in gastroenterology clinic. Thirty patients received conventional subcutaneous interferon alf...
متن کاملCutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy. However, several side effects are commonly observed and frequently lead to transient or definitive interruption of treatment. Although sarcoidosis in its systemic or cutaneous form is a very rare side effect in such circumstances, so...
متن کاملHigh Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C
BACKGROUND Hepatitis C is a major reason of morbidity and mortality among hemophilia patients. Although combination therapy with peginterferon (peg-INF) and ribavirin is considered as standard treatment for chronic hepatitis C (CHC), but more evidence of the efficacy and safety is needed. OBJECTIVES In this study, efficacy and tolerability of combination therapy with peginterferon α-2a-ribavi...
متن کاملVitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review
A 72-year-old female and a 57-year-old male with chronic hepatitis C were treated with a combination therapy of pegylated interferon (PEG-IFN)-α 2a (180 μg s.c. once a week) and ribavirin (1,000 mg orally daily). This resulted in the destruction of melanocytes at the injection site in both patients. In the male patient, the depigmentation progressed to the surrounding skin area. The dermatologi...
متن کاملHighly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
BACKGROUND/AIMS Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the safety and efficacy of combination therapy with peginterferon α-2a plus ribavirin for CHC in hemophilia. METHODS Patients (n=115) were enrolled between March 2007 and December 2008. Seventy-seven patie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
دوره 2011 شماره
صفحات -
تاریخ انتشار 2011